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Background
The efficacy and safety of icatibant for the treatment of
edematous hereditary angioedema (HAE) attacks was
established in three Phase III trials, including the For
Angioedema Subcutaneous Treatment-3 study (FAST-3;
NCT00912093). Here, data from the double-blind, con-
trolled phase and open-label extension (OLE) of FAST-3
were analyzed post-hoc to specifically evaluate icatibant
for the treatment of laryngeal attacks, which can cause
potentially fatal airway obstruction.
Methods
Controlled phase: adults with HAE type I/II were rando-
mized to a single subcutaneous injection of icatibant 30
mg or placebo for their first mild-to-moderate laryngeal
attack or moderate-to-very severe cutaneous/abdominal
attack; severe laryngeal attacks were treated with open-
label icatibant. OLE: attacks were treated with up to three
icatibant injections, at ≥6-hour intervals. Three outcomes
were analyzed for first icatibant-treated laryngeal attacks:
1) time to onset of symptom relief (earliest of three conse-
cutive measurements for which there was a 50% reduction
of patient–assessed 5-symptom composite 100 mm visual
analog scale [VAS]); 2) time to almost complete symptom
relief (earliest of three consecutive measurements for
which all VAS symptom scores <10 mm); 3) patient- and
investigator-assessed time to initial symptom improve-
ment. Reinjection rates were also recorded.
Results
For first icatibant-treated laryngeal attacks in the con-
trolled phase or OLE (n=27), median (95% CI) time to
onset of symptom relief was 2.0 (1.5-3.5) hours, median
(95% CI) time to almost complete symptom relief was
6.0 (3.0–24.3) hours, and median (95% CI) patient- and
investigator-assessed time to initial symptom improve-
ment was 0.7 (0.4-0.9) and 0.8 (0.5-1.1) hours, respectively.
In the OLE, 41/43 (95.3%) laryngeal attacks were treated
with one icatibant injection, 2/43 (4.7%) were treated with
two injections, and none required three injections.
Conclusions
Icatibant provided symptom relief for mild-to-severe lar-
yngeal HAE attacks in FAST-3. In the OLE, almost all
laryngeal attacks were treated with one injection only.
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